Rigel Pharmaceuticals (RIGL) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.The upward trend in estimate revisions for this drug developer reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estima ...

Key Takeaways Stocks like B, TREE, and RIGL are outperforming the S&P 500 across 1, 4, and 12-week periods.These picks also show upward earnings revisions and strong VGM Scores of A or B.Standouts include RIGL,with 198.1% stock gain and TREE's 70.8% average earnings surprise.After a strong run last month, U.S. stocks have hit a patch of turbulence. Tariff headlines, including sweeping new levies on key partners and chip imports, spooked markets and pushed the S&P 500 to its biggest loss in months. Job growt ...

From a technical perspective, Rigel Pharmaceuticals, Inc. (RIGL) is looking like an interesting pick, as it just reached a key level of support. RIGL's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a lo ...

Shares of Rigel Pharmaceuticals (RIGL) have been strong performers lately, with the stock up 56.6% over the past month. The stock hit a new 52-week high of $30.43 in the previous session. Rigel has gained 77.2% since the start of the year compared to the -7.6% gain for the Zacks Medical sector and the 5.6% return for the Zacks Medical - Drugs industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of ...

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $3.28 per share, beating the Zacks Consensus Estimate of $1.97 per share. This compares to a loss of $0.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +66.50%. A quarter ago, it was expected that this drug developer would post earnings of $0.14 per share when it actually produced earnings of $0.63, delivering a surprise of +350%.Over the last four quarters, t ...

Rigel Pharmaceuticals (RIGL) Q2 2025 Earnings Call August 05, 2025 04:30 PM ET Speaker0Greetings and welcome to Rigel Pharmaceuticals Financial Conference Call for the Second Quarter twenty twenty five. At this time, all participants are in a listen only mode. A brief question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce our first speaker, Ray Furey, Rigel's Executive Vice President, General Counsel and Corporate ...

1 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955 ("PSLRA") relating to, among other things, continued development and expansion of our business, projected financial performance including sales and revenue growth, continued advancement of our R289 study, future Phase 2 studies of olutasidenib in recurrent glioma, potential identification of opportunities and completion of acquisition or in-license of ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-29889 Rigel Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3248524 (Sta ...

Exhibit 99.1 Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., August 5, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the second quarter ended June 30, 2025, including sales of TAVALISSE (fostamatinib disodium hexahydrate), GAVRETO (pralsetinib) and REZLIDHIA (olutasidenib), and recent business progress. "Ou ...

Second quarter 2025 total revenue of approximately $101.7 million, which includes net product sales of $58.9 million and contract revenues from collaborations of $42.7 million  Completed enrollment in the dose escalation part of the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in patients with R/R lower-risk MDS Generated $59.6 million of net income in the second quarter of 2025 Updated 2025 Outlook: Total revenue of approximately $270 to $280 million, which includes net product sales ...